Literature DB >> 11096652

Transcatheter Closure of Secundum Atrial Septal Defects Using the Amplatzer Septal Occluder: Clinical Experience and Technical Considerations.

.   

Abstract

The Amplatzer septal occluder (AGA Medical Corporation, Golden Valley, MN) is designed to be an ideal device for the transcatheter closure of ostium secundum atrial septal defects. This device is user-friendly and has a complete closure rate of greater than 96% and few complications. It is easily retrievable and repositionable. It is also useful for closure of other types of shunts. Large atrial septal defects (ASDs) of up to 38 mm may now be closed. The use of the transesophageal echocardiogram (TEE) for evaluation of device placement is also reviewed.

Entities:  

Year:  2000        PMID: 11096652

Source DB:  PubMed          Journal:  Curr Interv Cardiol Rep        ISSN: 1523-3839


  5 in total

1.  Use of the transseptal puncture in transcatheter closure of long tunnel-type patent foramen ovale.

Authors:  C J McMahon; H G El Said; C E Mullins
Journal:  Heart       Date:  2002-08       Impact factor: 5.994

2.  A noninvasive sizing method to choose fitted Amplatzer septal occluder by transthoracic echocardiography in patients with secundum atrial septal defects.

Authors:  Kuang-Jen Chien; Cheng-Liang Lee; Ta-Cheng Huang; Chu-Chuan Lin; Ken-Pen Weng; Shih-Hui Huang; Kai-Sheng Hsieh
Journal:  Heart Vessels       Date:  2007-07-20       Impact factor: 2.037

3.  Biocompatibility of septal defect closure devices.

Authors:  Matthias Sigler; Christian Jux
Journal:  Heart       Date:  2006-10-11       Impact factor: 5.994

4.  Experience with transcatheter closure of secundum atrial septal defects using the Amplatzer septal occluder: a single centre study in 236 consecutive patients.

Authors:  G Fischer; J Stieh; A Uebing; U Hoffmann; G Morf; H H Kramer
Journal:  Heart       Date:  2003-02       Impact factor: 5.994

5.  Practical Therapeutic Management of Percutaneous Atrial Septal Defect Closure.

Authors:  Shuhei Tanaka; Teruhiko Imamura; Nikhil Narang; Nobuyuki Fukuda; Hiroshi Ueno; Koichiro Kinugawa
Journal:  Intern Med       Date:  2021-02-15       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.